<DOC>
	<DOCNO>NCT02201667</DOCNO>
	<brief_summary>The goal acute coronary syndrome ( ACS ) therapy successfully restore epicardial blood flow myocardial perfusion . Percutaneous coronary intervention ( PCI ) document effective method restoration epicardial blood flow . However , epicardial blood flow necessarily equate myocardial perfusion . Clopidogrel bind irreversibly platelet P 2 Y 12 receptor inhibit platelet aggregation , main limitation slow onset , prevention recovery platelet function , interindividual variability . Clinical pharmacology early dose-finding study suggest faster onset great consistent inhibition platelet aggregation ( IPA ) ticagrelor compare clopidogrel . Two currently main method angiographic assessment myocardial perfusion include thrombolysis myocardial infarction ( TIMI ) myocardial perfusion grading ( TMPG ) myocardial blush grading ( MBG ) . These establish myocardial perfusion parameter widely use various important trial report highly useful predict clinical outcome . However , visual assessment method categorical , subjective , operator dependent contrast myocardium use cine-angiographic frame-counting , develop investigator ' center quantify myocardial tissue- level perfusion prove predictive value clinical prognosis . Thus , investigator aim initiate open-label study evaluate acute efficacy treatment ticagrelor versus clopidogrel myocardial tissue-level perfusion assess Myocardial Perfusion Frame Count ( TMPFC ) magnetic resonance imaging ( MRI ) patient high-risk non-ST elevation acute coronary syndrome ( NSTE-ACS ) undergo early percutaneous coronary intervention ( PCI ) . The investigator hypothesize compare clopidogrel , ticagrelor significantly improve myocardial perfusion assess Myocardial Perfusion Frame Count ( TMPFC ) high-risk non-ST elevation acute coronary syndrome ( NSTE-ACS ) patient undergo early percutaneous coronary intervention ( PCI ) , without additional increase major bleeding .</brief_summary>
	<brief_title>Efficacy Ticagrelor v Clopidogrel High-risk NSTE-ACS Patients Undergoing Early PCI</brief_title>
	<detailed_description>The goal acute coronary syndrome ( ACS ) therapy successfully restore epicardial blood flow myocardial perfusion . Percutaneous coronary intervention ( PCI ) document effective method restoration epicardial blood flow . However , epicardial blood flow necessarily equate myocardial perfusion ; every patient thrombolysis myocardial infarction ( TIMI ) 3 flow successful percutaneous coronary intervention ( PCI ) achieve effective myocardial tissue-level perfusion . Although epicardial thrombolysis myocardial infarction ( TIMI ) 3 flow could restore &gt; 90 % acute coronary syndrome ( ACS ) patient undergo percutaneous coronary intervention ( PCI ) , normalization myocardial perfusion achieve less frequently , detrimental impact survival . Clopidogrel , widely use antiplatelet agent acute coronary syndrome ( ACS ) , thienopyridine prodrug , inactive undergoes biotransformation active metabolite , bind irreversibly platelet P 2 Y 12 receptor . This irreversible binding mean receptor inhibit lifespan platelet . The main limitation clopidogrel administration include slow onset , prevention recovery platelet function , interindividual variability . Clinical pharmacology early dose-finding study suggest faster onset great consistent inhibition platelet aggregation ( IPA ) ticagrelor compare clopidogrel . ONSET/OFFSET study show patient stable coronary artery disease aspirin , ticagrelor demonstrate rapid onset pharmacological effect , demonstrate mean platelet aggregation ( IPA ) ticagrelor 0.5 h 180 mg load dose 41 % , maximum platelet aggregation ( IPA ) effect 87.9-89.6 % 2-4 hour post dose . A total 90 % patient final extent Inhibition platelet aggregation ( IPA ) &gt; 70 % 2 h post-dose . The high inhibition platelet aggregation ( IPA ) effect ticagrelor ( 87 % 89 % ) maintain 2-8 hour . Ticagrelor might overcome slow-onset limitation clopidogrel bring extra benefit improve myocardial perfusion acute phase acute coronary syndrome ( ACS ) undergo early percutaneous coronary intervention ( PCI ) . Currently , two main method angiographic assessment myocardial perfusion : Thrombolysis myocardial infarction ( TIMI ) myocardial perfusion grading ( TMPG ) , describe Gibson et al . myocardial blush grading ( MBG ) , describe Va n't Hof et al . These establish myocardial perfusion parameter , myocardial perfusion grading ( TMPG ) , myocardial blush grading ( MBG ) , widely use various important trial report highly useful predict clinical outcome . However , visual assessment method categorical , subjective , operator dependent . Thrombolysis myocardial infarction ( TIMI ) Myocardial Perfusion Frame Count ( TMPFC ) , novel objective method measure fill clearance contrast myocardium use cine-angiographic frame-counting , develop investigator ' center quantify myocardial tissue- level perfusion prove predictive value clinical prognosis . Thus , investigator aim initiate open-label study evaluate acute efficacy treatment ticagrelor versus clopidogrel myocardial tissue-level perfusion assess Myocardial Perfusion Frame Count ( TMPFC ) magnetic resonance imaging ( MRI ) patient high-risk non-ST elevation acute coronary syndrome ( NSTE-ACS ) undergo early percutaneous coronary intervention ( PCI ) .</detailed_description>
	<mesh_term>Acute Coronary Syndrome</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<mesh_term>Ticlopidine</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Ticagrelor</mesh_term>
	<criteria>For inclusion study subject fulfill follow criterion : 1 . Provision inform consent prior study specific procedure ; 2 . Men woman &gt; 18 year age , document evidence nonST segment elevation Acute Coronary Syndrome ( ACS ) 24 hour randomisation ; 3 . Hospitalized highrisk nonST segment elevation Acute Coronary Syndrome ( ACS ) ( GRACE risk score＞140 ) indication early percutaneous coronary intervention ( PCI ) accord 2012 Chinese nonS T segment elevation Acute Coronary Syndrome ( ACS ) guideline recommendation . Subjects enter study follow exclusion criterion fulfil : 1 . Evidence cardiac rupture ; 2 . History major hemorrhage ( intracranial , gastrointestinal , etc . ) ; 3 . Active pathological bleeding ; 4 . Acute chronic hematologic disorder include Hemoglobin le 10 g/L platelet count le 10×109/L procedure ; 5 . Contraindication use clopidogrel ticagrelor ; 6 . Subject condition , opinion investigator , participation would best interest subject ( eg , compromise wellbeing ) could prevent , limit , confound protocolspecified assessment . 7 . Severe complication 7.1 Other disease life expectancy ≤12 month ; 7.2 Any history Severe renal hepatic dysfunction ( hepatic failure , cirrhosis , portal hypertension active hepatitis ) ; Neutropenia , thrombocytopenia ; Known acute pancreatitis ; 7.3 Arterial aneurysm , arterial/venous malformation aorta dissection ; 8 . Complex heart condition 8.1 PCI within previous 1 month Previous coronaryartery bypass surgery ( CABG ) ; 8.2 History myocardial infarction ; 8.3 Previously know multivessel coronary artery disease suitable percutaneous coronary intervention ( PCI ) ; 9 . Previous enrolment study treatment investigational drug device another study protocol past 30 day ; 10 . Treatment anticoagulant ; 11 . Pregnancy lactate ; 12 . Body weight &lt; 40kg &gt; 125kg ; 13 . Known hypersensitivity drug may appear study ; 14 . Inability follow protocol comply followup requirement reason investigator feel would place patient increase risk ;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>non-ST elevation acute coronary syndrome</keyword>
	<keyword>myocardial perfusion</keyword>
	<keyword>magnetic Resonance Imaging</keyword>
	<keyword>antiplatelet</keyword>
</DOC>